Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2016

22.02.2016 | Original Article

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors

verfasst von: Varun Goel, Eunju Hurh, Andrew Stein, Jerry Nedelman, Jocelyn Zhou, Ovidiu Chiparus, Pai-Hsi Huang, Sven Gogov, Dalila Sellami

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate effects.

Methods

PK data from five phase 1 or 2 studies (N = 436) in the dose range from 100 to 3000 mg were analyzed using NONMEM. A two-compartment base model with first-order absorption, lag time, linear elimination, and bioavailability that decreased with dose was updated to describe the PK of sonidegib. Covariate analyses were performed and were incorporated into the population PK full model.

Results

The base and full models were robust with a good fit to the study data. Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %). Clinically relevant covariate effects were: A high-fat meal increased sonidegib bioavailability fivefold, healthy volunteers had threefold higher clearance, sonidegib bioavailability decreased with increasing dose levels, and PPI coadministration reduced sonidegib bioavailability by 30 %. Sonidegib PK was not significantly impacted by baseline age, weight, total bilirubin, alanine aminotransferase, albumin, creatinine clearance, gender, and ethnicity (Western countries versus Japanese).

Conclusion

No dose adjustment is needed for mild hepatic impairment, mild and moderate renal impairment, age, weight, gender, or ethnicity. This population PK model adequately characterizes sonidegib PK characteristics and can be used for various simulations and applications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat di Magliano MP, Hebrok M (2003) Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3(12):903–911CrossRef di Magliano MP, Hebrok M (2003) Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3(12):903–911CrossRef
2.
Zurück zum Zitat McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114CrossRefPubMed McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114CrossRefPubMed
3.
Zurück zum Zitat Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805(2):181–208PubMed Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805(2):181–208PubMed
5.
Zurück zum Zitat Buonamici S et al (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2(51):5170 Buonamici S et al (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2(51):5170
6.
Zurück zum Zitat Rodon J et al (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumours. Clin Cancer Res 20(7):1900–1909CrossRefPubMed Rodon J et al (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumours. Clin Cancer Res 20(7):1900–1909CrossRefPubMed
7.
Zurück zum Zitat Slade I et al (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 10(2):337–342CrossRefPubMed Slade I et al (2011) Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 10(2):337–342CrossRefPubMed
8.
Zurück zum Zitat Zurawel RH et al (2000) Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27(1):44–51CrossRefPubMed Zurawel RH et al (2000) Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27(1):44–51CrossRefPubMed
9.
Zurück zum Zitat Xie J et al (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90–92CrossRefPubMed Xie J et al (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391(6662):90–92CrossRefPubMed
10.
Zurück zum Zitat Reifenberger J et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152(1):43–51CrossRefPubMed Reifenberger J et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152(1):43–51CrossRefPubMed
11.
Zurück zum Zitat Ling G et al (2001) PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20(53):7770–7778CrossRefPubMed Ling G et al (2001) PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20(53):7770–7778CrossRefPubMed
13.
Zurück zum Zitat Migden MR et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716–728CrossRefPubMed Migden MR et al (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716–728CrossRefPubMed
14.
Zurück zum Zitat Zollinger M et al (2014) Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74(1):63–75CrossRefPubMed Zollinger M et al (2014) Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74(1):63–75CrossRefPubMed
15.
Zurück zum Zitat Novartis Pharmaceuticals Corporation Data on File (2015) Novartis Pharmaceuticals Corporation Data on File (2015)
16.
Zurück zum Zitat Zhou J, Hurh E, Emotte C, Winter S, Quinlan M, Austin T, Kalambakas S, Wang Y (2014) Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug-drug interaction study with rifampicin and ketoconazole in healthy subjects. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, 2014. abstract LBI-021 Zhou J, Hurh E, Emotte C, Winter S, Quinlan M, Austin T, Kalambakas S, Wang Y (2014) Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug-drug interaction study with rifampicin and ketoconazole in healthy subjects. In: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, 2014. abstract LBI-021
17.
Zurück zum Zitat Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(1):14–26CrossRefPubMed Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(1):14–26CrossRefPubMed
18.
Zurück zum Zitat Gibaldi M, Perrier D (1972) Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci 61(6):952–954CrossRefPubMed Gibaldi M, Perrier D (1972) Drug elimination and apparent volume of distribution in multicompartment systems. J Pharm Sci 61(6):952–954CrossRefPubMed
19.
Zurück zum Zitat Gastonguay M (2011) full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe 2011. A16 Gastonguay M (2011) full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe 2011. A16
Metadaten
Titel
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors
verfasst von
Varun Goel
Eunju Hurh
Andrew Stein
Jerry Nedelman
Jocelyn Zhou
Ovidiu Chiparus
Pai-Hsi Huang
Sven Gogov
Dalila Sellami
Publikationsdatum
22.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-2982-1

Weitere Artikel der Ausgabe 4/2016

Cancer Chemotherapy and Pharmacology 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.